Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Following last week’s IPO market performance, which saw three biotechs raise more than $740 million, a trio of preclinical companies are now preparing for their at bat. The IPO queue also gained five more companies seeking NASDAQ listings on Friday, signaling a continued appetite for fresh biopharma paper.

Gene therapy company Generation Bio Co., vaccines play Vaxcyte Inc., and antibody-oligonucleotide conjugate company Avidity Biosciences LLC set terms for their NASDAQ IPOs Monday. Cancer diagnostic company Burning Rock Biotech Ltd. has also set its IPO range along with Royalty Pharma plc., which could have the largest healthcare IPO of the year so far...